Development and in vivo evaluation of an oral drug delivery system for paclitaxel

Biomaterials

Volumn 32, Issue 1, 2011, Pages 170-175

  Iqbal, Javed ^a   Sarti, Federica ^a   Perera, Glen ^a   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cytochrome P450; Oral drug delivery; P Glycoprotein; Paclitaxel; Poly(acrylic acid) cysteine; Thiomers

Indexed keywords

CYTOCHROME P450; ORAL DRUG DELIVERY; P-GLYCOPROTEIN; PACLITAXEL; POLY(ACRYLIC ACID ); THIOMERS;

ABSORPTION; AMINO ACIDS; BIOCHEMISTRY; CARBOXYLIC ACIDS; DRUG DELIVERY; GLYCOPROTEINS; MONOLAYERS; ORGANIC ACIDS; SUBSTRATES;

HYDROGELS;

ANTINEOPLASTIC AGENT; CYSTEINE; CYTOCHROME P450; EXCIPIENT; GLUTATHIONE; GLYCOPROTEIN P; PACLITAXEL; POLYACRYLIC ACID; POLYMER; THIOMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; CONTROLLED STUDY; DISULFIDE BOND; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONOLAYER CULTURE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SYNTHESIS;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PACLITAXEL; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY;

PAA; RATTUS;

EID: 78349308871     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.036     Document Type: Article

References (26)

1. Rowinsky E.K., Onetto N., Canetta R.M., Arbuck S.G. Paclitaxel: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992, 9:646-662.
2. Syrigou E., Makrilia N., Koti I., Saif M.W., Syrigos K.N. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs 2009, 20:1-6.
3. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
4. Letchford K., Liggins R., Wasan K.M., Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 2009, 71:196-206.
5. Nornoo A.O., Zheng H., Lopes L.B., Johnson-Restrepo B., Kannan K., Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009, 71:310-317.
6. Roy V., LaPlant B.R., Gross G.G., Bane C.L., Palmieri F.M. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009, 20:449-453.
7. van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997, 76:1181-1183.
8. Walle T. Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol 1996, 272:145-151.
9. Bernkop-Schnürch A., Schwarz V., Steininger S. Polymers with thiol groups: a new generation of mucoadhesive polymers?. Pharm Res 1999, 16:876-881.
10. Clausen A.E., Bernkop-Schnürch A. In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil. J Pharm Sci 2000, 89:1253-1261.
11. Kast C.E., Guggi D., Langoth N., Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res 2003, 20:931-936.
12. Werle M., Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release 2006, 111:41-46.
13. Iqbal J, Bernkop-Schnürch. Thiolated polymers: CYP2A6 and CYP3A4 inhibition. Life Science Meeting _Innsbruck Universities Igls, Austria 2009; P29: 40.
14. Marschütz M.K., Bernkop-Schnürch A. Thiolated polymers: advance in mucoadhesion by use of in-situ crosslinking poly(acrylic acid)-cysteine conjugates. Eur J Pharm Sci 2002, 15:387-394.
15. Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 1990, 79:476-482.
16. Yu H., Straubinger R.M., Cao J., Wang H., Qu J. Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry. J Chromatogr A 2008, 1210:160-167.
17. Demirbas S., Stavchansky S. Effects of citicholine and dimethylsulfoxide on trnasepithelial transport of passively diffused drugs in the Caco-2 cell culture model. Int J Pharm 2003, 251:107-112.
18. Föger F. Krum Kafedjiiski, Hoyer H, Loretz B, Bernkop-Schnürch A. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J Drug Target 2007, 15:132-139.
19. Vigl C., Leithner K., Albrecht K., Bernkop-Schnürch A. The efflux pump inhibitory properties of (thiolated) polyallylamines. J Drug Deliv Sci Technol 2009, 19:405-411.
20. Lo Y.L., Huang J.D. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000, 59:665-672.
21. Al-Shawi M.K., Urbatsch I.L., Senior A.E. Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 1994, 269:8986-8992.
22. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
23. Bardelmeijer H.A., Ouwehand M., Beijnen J.H., Schellens J.H., van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004, 22:219-229.
24. Woo J.S., Lee C.H., Shim C.K., Hwang S.J. Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-glycoprotein Inhibitor KR30031. Pharm Res 2003, 20:24-30.
25. Varma M.V.S., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005, 25:445-453.
26. Jin J., Bi H., Hu J., Zhong G., Zhao L., Huang Z., et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm Drug Dispos 2010, 31:264-268.